parthenolide has been researched along with Liver Cirrhosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, ZY; Dou, JY; Jiang, YC; Lian, LH; Nan, JX; Song, J; Wang, G; Wu, YL; Zhang, J | 1 |
| Kim, DG; Kim, IH; Kim, SH; Kim, SW; Lee, MJ; Lee, SO; Lee, ST; Park, WH | 1 |
2 other study(ies) available for parthenolide and Liver Cirrhosis
| Article | Year |
|---|---|
Parthenolide, bioactive compound of Chrysanthemum parthenium L., ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway.
Topics: Inflammation; Liver Cirrhosis; Sesquiterpenes; Signal Transduction; STAT3 Transcription Factor; Tanacetum parthenium; Toll-Like Receptor 4 | 2021 |
Parthenolide-induced apoptosis of hepatic stellate cells and anti-fibrotic effects in an in vivo rat model.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Gene Expression; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Membrane Potential, Mitochondrial; NF-kappa B; Oxidative Stress; Rats; Reactive Oxygen Species; Sesquiterpenes; Thioacetamide; Tumor Necrosis Factor-alpha | 2012 |